Genetic variation of the serotonin transporter gene (SLC6A4) has been suggested as potential mediator for antidepressant response in patients with depression. This study aimed to determine whether DNA methylation in SLC6A4 changes after antidepressant treatment and whether it affects treatment response in patients with depression. Overall, 221 Korean patients with depression completed 6 weeks of selective serotonin reuptake inhibitor (SSRI) monotherapy. DNA was extracted from venous blood pre- and post-treatment, and DNA methylation was analyzed using polymerase chain reaction. We used Wilcoxon's signed-rank test to verify the difference in methylation after treatment. Treatment response was assessed using the 17-item Hamilton Depression Rating Scale, and mRNA levels were quantified.

中文翻译：

---

抗抑郁治疗对韩国重度抑郁症患者 SLC6A4 甲基化的影响

5-羟色胺转运蛋白基因 ( SLC6A4 ) 的遗传变异被认为是抑郁症患者抗抑郁反应的潜​​在介质。本研究旨在确定SLC6A4中的 DNA 甲基化在抗抑郁治疗后是否发生变化，以及它是否影响抑郁症患者的治疗反应。总体而言，221 名韩国抑郁症患者完成了 6 周的选择性血清素再摄取抑制剂 (SSRI) 单一疗法。从处理前后的静脉血中提取 DNA，并使用聚合酶链反应分析 DNA 甲基化。我们使用 Wilcoxon 的符号秩检验来验证处理后甲基化的差异。使用 17 项汉密尔顿抑郁量表评估治疗反应，并量化 mRNA 水平。